within Pharmacolibrary.Drugs.C_CardiovascularSystem.C07B_BetaBlockingAgentsAndThiazides.C07BB04_AcebutololAndThiazides;

model AcebutololAndThiazides
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.4,
    Cl = 4.166666666666667e-06,
    adminDuration = 600,
    adminMass = 400 / 1000000,
    adminCount = 1,
    Vd = 0.0035,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0006666666666666666,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>AcebutololAndThiazides</td></tr><tr><td>ATC code:</td><td>C07BB04</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>400</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>3.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>250</td><td>ml/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Combination of acebutolol, a cardioselective beta-adrenergic blocker, and thiazide diuretics (typically hydrochlorothiazide), used for the management of hypertension. This drug combination is approved in some regions for the treatment of high blood pressure to reduce the risk of cardiovascular events.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic parameters are available for the acebutolol and thiazides fixed-dose combination product; estimates are based on available monotherapy PK data in healthy adults.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C07BB04 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end AcebutololAndThiazides;
